Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Can-Fite BioPharma ( (CANF) ) has provided an update.
On December 16, 2025, Can-Fite BioPharma Ltd. provided an update on its clinical and financial status. The company is actively enrolling patients in pivotal Phase III studies for its Namodenoson drug candidate in advanced hepatocellular carcinoma and Piclidenoson for psoriasis. Additionally, Namodenoson is in Phase II trials for metabolic dysfunction-associated steatohepatitis and pancreatic cancer. Financially, Can-Fite reported having $6.45 million in cash and cash equivalents as of June 30, 2025, and raised additional funds through a public offering and ATM facility. These developments reflect Can-Fite’s strategic focus on addressing unmet medical needs with its drug candidates, potentially enhancing its market position and stakeholder value.
The most recent analyst rating on (CANF) stock is a Hold with a $0.37 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Neutral.
Can-Fite BioPharma’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and persistent losses. Technical analysis also indicates weak momentum, with the stock trading below key moving averages. Valuation is difficult to assess due to the lack of earnings and dividends.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is a biotechnology company focused on developing small-molecule drugs for oncological and inflammatory diseases. The company is advancing clinical-stage drug candidates targeting multi-billion-dollar markets in cancer, liver, and inflammatory diseases. Its lead drug candidates include Piclidenoson for psoriasis and Namodenoson for hepatocellular carcinoma, metabolic dysfunction-associated steatohepatitis, and pancreatic cancer.
Average Trading Volume: 6,392,362
Technical Sentiment Signal: Sell
Current Market Cap: $24.45M
Learn more about CANF stock on TipRanks’ Stock Analysis page.